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The Epstein-Barr virus (EBV) immediate-early (IE) protein BRLF1 (R) is a transcription factor that induces
the lytic form of EBV infection. R activates certain early viral promoters through a direct binding mechanism
but induces transcription of the other EBV IE gene, BZLF1 (Z), indirectly through cellular factors binding to
a CRE motif in the Z promoter (Zp). Here we demonstrate that R activates expression of the fatty acid synthase
(FAS) cellular gene through a p38 stress mitogen-activated protein kinase-dependent mechanism. B-cell
receptor engagement of Akata cells also increases FAS expression. The FAS gene product is required for de
novo synthesis of the palmitate fatty acid, and high-level FAS expression is normally limited to liver, brain,
lung, and adipose tissue. We show that human epithelial tongue cells lytically infected with EBV (from oral
hairy leukoplakia lesions) express much more FAS than uninfected cells. Two specific FAS inhibitors, ceru-
lenin and C75, prevent R activation of IE (Z) and early (BMRF1) lytic EBV proteins in Jijoye cells. In addition,
cerulenin and C75 dramatically attenuate IE and early lytic gene expression after B-cell receptor engagement
in Akata cells and constitutive lytic viral gene expression in EBV-positive AGS cells. However, FAS inhibitors
do not reduce lytic viral gene expression induced by a vector in which the Z gene product is driven by a strong
heterologous promoter. In addition, FAS inhibitors do not reduce R activation of a naked DNA reporter gene
construct driven by the Z promoter (Zp). These results suggest that cellular FAS activity is important for
induction of Z transcription from the intact latent EBV genome, perhaps reflecting the involvement of
lipid-derived signaling pathways or palmitoylated proteins. Furthermore, using FAS inhibitors may be a
completely novel approach for blocking the lytic form of EBV replication.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
that causes infectious mononucleosis. EBV has also been
found in association with a variety of cancers, including Bur-
kitt’s lymphoma, nasopharyngeal carcinoma, gastric carci-
noma, B-cell lymphomas in immunosuppressed patients, and
Hodgkin’s disease (28, 46). EBV can infect cells in either a lytic
or latent form. EBV infection of epithelial cells usually results
in the lytic form of infection, whereas the virus usually remains
latent in B cells (28, 46, 52). However, the virus periodically
converts to the lytic form of infection in a small percentage of
B cells. This viral reactivation is initiated by the two EBV
immediate-early (IE) proteins, BZLF1 (Z) and BRLF1 (R) (8,
10, 18, 44, 47, 54, 64, 69), which are transcriptional activators
(11, 16, 24, 25, 27, 32, 56).
Regardless of which EBV IE gene is initially transcribed,
expression of either IE protein leads first to the expression of
the other IE protein (1, 18, 69), and then the two IE proteins
together induce full activation of the viral early genes. Z acti-
vates the R promoter by directly binding to Z-response ele-
ments in the R promoter (1, 33, 51). Although R activates
certain early genes, such as BMRF1 and BHRF1, through a
direct binding mechanism (22, 43), R activation of the IE Z
promoter (Zp) is mediated through cellular transcription fac-
tors (including ATF-2 and c-Jun) that bind to a CRE site (ZII)
in this promoter (3). R activates the stress mitogen-activated
protein (MAP) kinases (p38 and c-Jun N-terminal kinase) (3),
which phosphorylate and activate ATF-2 and c-Jun. In addi-
tion, R activates phosphatidylinositol 3 (PI3) kinase (13), and
PI3 kinase activity is required for R-mediated induction of lytic
viral gene transcription. However, at this time, it is not clear
how the R protein, which is primarily nuclear, activates these
various signal transduction pathways.
In this paper, we show that R induces expression of a cellular
gene, the fatty acid synthase (FAS) gene, in host cells. The
FAS enzyme is required for the production of palmitate, a
saturated free 16-carbon fatty acid (50, 53, 60). FAS activity is
important for the synthesis of cellular membranes as well as a
variety of different lipid substrates. In addition, certain pro-
teins are posttranslationally modified by palmitoylation of cys-
teine residues, and in some cases, palmitoylation helps localize
proteins to lipid rafts (4, 15). Although high-level FAS expres-
sion is normally limited to liver, lung, brain, and intra-abdom-
inal adipose tissue (50), a variety of cancers have also recently
been shown to overexpress FAS (29, 39). Interestingly, a spe-
cific FAS inhibitor, C75, preferentially inhibits the growth of
tumor cells versus primary cells (30, 42), suggesting that FAS
activity may be important for the growth of certain tumors. In
addition, the FAS inhibitor cerulenin inhibits the replication of
several different viruses, including varicella-zoster virus, al-
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though the exact mechanisms for these effects have not been
well defined (9, 23, 38).
Somewhat surprisingly, we demonstrate here that cellular
FAS activity appears to be essential for lytic EBV gene induc-
tion in latently infected cells. Using two different specific FAS
inhibitors, cerulenin and C75, we show that FAS activity is
required for R-mediated induction of IE (Z) and early
(BMRF1) lytic genes in Jijoye cells, for the induction of Z, R,
and BMRF1 transcription after cross-linking of the B-cell re-
ceptor in Akata cells, and for constitutively lytic gene expres-
sion in EBV-infected gastric carcinoma (AGS) cells. In con-
trast, FAS inhibitors do not prevent a plasmid that contains the
Z gene product under the control of a strong heterologous
promoter from inducing lytic gene expression in Jijoye cells. In
addition, FAS is not required for R activation of the Z pro-
moter in the context of a naked DNA reporter gene construct.
These results suggest that cellular FAS activity is important
for efficient activation of Z transcription from the intact latent
EBV genome. Although the precise mechanism by which FAS
activity contributes to Z transcription is not yet known, we
speculate that lipid-derived signal transduction pathways or
palmitoylated proteins may be involved in the activation of Z
transcription in latently infected cells. In any event, the ability
of R, as well as B-cell receptor engagement, to activate FAS
expression in host cells that would otherwise express minimal
FAS likely plays a key role in enhancing the efficiency of lytic
viral gene expression. Conversely, agents that inhibit FAS ac-
tivity may prove useful for preventing the lytic form of EBV
infection in patients.
MATERIALS AND METHODS
Cell lines. HeLa is a cervical carcinoma cell line and was maintained in
Dulbecco’s modified Eagle’s medium H supplemented with 10% fetal calf serum.
Telomerase-immortalized human keratinocytes (TIK) were a gift from A. J.
Klingelhutz at the University of Iowa and originally derived from human neo-
natal foreskin as previously described (17). TIK cells were maintained in kera-
tinocyte-SFM medium (Gibco-BRL) with epidermal growth factor and bovine
pituitary extract added. Akata and Jijoye cells are EBV-positive Burkitt’s lym-
phoma cell lines and were maintained in RPMI 1640 medium supplemented with
10% fetal calf serum. The EBV-positive AGS (gastric carcinoma) cell line was
established by infecting gastric carcinoma cells with an EBV containing a green
fluorescent protein (GFP)-hygromycin cassette as previously described (18) (a
gift from H.-J. Delecluse at the University of Birmingham, Birmingham, United
Kingdom). EBV-positive AGS cells were maintained in F12 nutrient mixture
(Gibco-BRL) with hygromycin selection. All cell lines were cultured at 37°C in a
5% CO2 incubator.
Adenovirus construction and infection. The EBV IE gene, BRLF1, and the
control lacZ gene, under control of the IE cytomegalovirus promoter, were
inserted via cre-loxP-mediated recombination into an adenovirus type 5 deriva-
tive lacking the E1 and E3 genes to create adenovirus-BRLF1 (AdR) and
adenovirus-LacZ (AdLacZ), as previously described (64). Virus stocks were
grown in 293 cells, purified by cesium chloride gradient treatment twice, followed
by dialysis. HeLa and TIK cells were plated at a density of 1.0  106 and 3  106
cells per 150-mm-diameter plate, respectively, 24 h prior to infection. Cells were
infected with no adenovirus (mock infection), AdLacZ, or AdR at a multiplicity
of infection (MOI) of 20. Cells were harvested 24 h postinfection for RNA
preparation.
Plasmids. The R and Z expression vectors contain the R and Z genomic
sequences, respectively, inserted in the pSG5 expression vector (Stratagene)
under the control of the simian virus 40 promoter (a gift from Diane Hayward)
(48). The Zp-CAT construct contains the Z promoter (Zp) sequences from
positions 221 to 12 linked to the chloramphenicol acetyltransferase (CAT)
gene (a gift from Erik Flemington) as previously described (19). Appropriate
vector controls were included in each experiment.
Transfection. Jijoye cells were transfected with 10 g of plasmid DNA by
electroporation with 1,500 V from a Zapper electroporation unit (Medical Elec-
tronics Shop, University of Wisconsin).
FAS inhibitor studies. In Jijoye cells, the FAS inhibitor cerulenin (Sigma) (10
g/ml) or C75 (Alexis Biochemicals) (10 g/ml) was added to media immediately
after electroporation of Z or R vector. In Akata cells, FAS inhibitors (cerulenin
[5 g/ml] or C75 [5 g/ml]) were added to the media 1 h prior to treatment with
anti-human immunoglobulin G (IgG) (Sigma) (0.1 mg/ml). Confluent EBV-
positive AGS cells were treated with FAS inhibitors (5 g/ml) for 48 h prior to
immunoblot analysis. The dimethyl sulfoxide (DMSO) vehicle was used as a
control in FAS inhibitor studies.
Reporter gene assays. Jijoye cells were cotransfected with the Zp-CAT con-
struct (1 g) and a control vector (SG5) (4 g) or the Zp-CAT construct (1 g)
and the SG5-R expression vector (4 g). The C75 FAS inhibitor was added to
some conditions immediately after electroporation. Cell extracts were prepared
72 h posttransfection and incubated at 37°C with [14C]chloramphenicol in the
presence of acetyl coenzyme A as described previously (20). The percent acet-
ylation of chloramphenicol was quantified by thin-layer chromatography fol-
lowed by PhosphorImager screening (Molecular Dynamics).
Northern blot analysis. Ten micrograms of total RNA, purified using the
Trizol reagent (Invitrogen) as specified by the manufacturer, was separated on a
1% formaldehyde gel and transferred to nylon membranes (Schleicher &
Schuell). Membranes were prehybridized for 25 min at 68°C in QuikHyb hybrid-
ization buffer (Stratagene) and then hybridized with randomly 32P-radiolabeled
probes for 1 h at 68°C. After hybridization, membranes were washed twice in a
solution consisting of 2 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) and 0.1% sodium dodecyl sulfate (SDS) at room temperature. The
membranes were then washed in 0.2 SSC–0.1% SDS for 5 to 10 min at 60°C.
The FAS probes were generated by reverse transcriptase PCR (RT-PCR) of 1 g
of total cellular RNA using the following primers: FAS sense 5-TTTCCCGAT
ATTCGGGCAGC-3 and FAS antisense 5-GTACATGAGCAGGCTCAGCC-
3. The PCR product was then randomly labeled. A randomly labeled (oligola-
beling kit; Amersham) mouse glyceraldehyde phosphate dehydrogenase probe
(Ambion) was used as a control.
RT-PCR. EBV-negative and EBV-positive Akata cells were treated with or
without anti-human IgG (Sigma; 0.1 mg/ml) for 24 h, and total RNA was iso-
lated. RT-PCR was performed using a kit according to the instructions of the
manufacturer (Promega). The FAS primers (sense, 5-TTTCCCGATATTCGG
GCAGC-3; antisense, 5-GTACATGAGCAGGCTCAGCC-3) were used to
synthesize the PCR products. PCR was run for 35 cycles, with 1 cycle consisting
of 30 s at 95°C, 30 s at 56°C, and 30 s at 72°C.
Immunoblot analysis. Immunoblot analysis of total cell extracts was per-
formed as previously described (2) with the following antibodies: anti--actin
mouse monoclonal antibody (Sigma) (diluted 1:5,000), anti-EBV BZLF1 (Ar-
gene) (diluted 1:100), anti-EBV BRLF1 (Argene) (diluted 1:100), and anti-EBV-
BMRF1 (Capricorn Products, Inc.) (diluted 1:100).
Patients and tissues. Oral hairy leukoplakia (OHL) biopsy specimens were
obtained from human immunodeficiency virus (HIV)-seropositive patients iden-
tified at the University of North Carolina (UNC) Hospitals. Biopsy specimens of
tissue from the lateral tongue border of healthy, HIV-negative subjects without
leukoplakia were used as controls. Specimens were immediately frozen and
stored at 80°C. A portion of each biopsy specimen was fixed in formalin and
sent to UNC Hospitals Department of Pathology for histopathologic diagnosis.
The presence of EBV in the OHL biopsy specimens was confirmed by detection
of the terminal restriction enzyme fragments on Southern blots (62).
Immunofluorescence. Frozen tissue sections were cut to a thickness of 5 m
and placed on poly-L-lysine-coated slides. Tissue sections and cell lines were fixed
in a chilled 1:1 mixture of methanol and acetone, blocked with 20% normal goat
serum, stained with a primary antibody for FAS (BD Biosciences) (diluted 1:20),
Z (Argene) (diluted 1:40), or R (Argene) (diluted 1:20) or with a isotype control
antibody, and then stained with fluorescein isothiocyanate (FITC)-conjugated
goat anti-mouse IgG (63). Slides were mounted with coverslips using Vectashield
(Vector Laboratories) and then examined by confocal laser-scanning micros-
copy.
Affymetrix GeneChip analysis. TIK cells were plated at a cell density of 2 
107 per 150-mm-diameter dish and then either mock infected or infected with
adenovirus expressing LacZ or R at an MOI of 17. The cells were harvested 48 h
later, and total RNA was obtained using the RNAeasy kit (Qiagen). From each
condition, cDNA was then synthesized using a T7-(dT)24 primer (cDNA kit from
Life Technologies). Biotinylated cRNA was then generated from the cDNA
reaction mixture using the BioArray high-yield RNA transcript kit. The cRNA
was then fragmented in fragmentation buffer (5 fragmentation buffer consists
of 200 mM Tris-acetate [pH 8.1], 500 mM potassium acetate, and 150 mM
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magnesium acetate) at 94°C for 35 min before the chip hybridization. Fifteen
micrograms of fragmented cRNA was then added to a hybridization cocktail.
The hybridization cocktail contains the following ingredients: 0.05 g of frag-
mented cRNA per l; 50 pM control oligonucleotide B2; BioB, BioC, BioD, and
cre hybridization controls; 0.1 mg of herring sperm DNA per ml; 0.5 mg of
acetylated bovine serum albumin per ml; 100 mM morpholineethanesulfonic acid
(MES); 1 M Na; 20 mM EDTA; 0.01% Tween 20; and the GeneChip Hu-
GeneFL array, which provides gene expression data for approximately 5,000
full-length human sequences. Arrays were hybridized for 16 h in the GeneChip
fluidics station 400 and were washed and scanned with the Hewlett-Packard
GeneArray scanner. During the washing, the cRNA probe was labeled with
R-phycoerythrin streptavidin. Affymetrix GeneChip Microarray Suite 4.0 soft-
ware was used for washing, scanning, and basic analysis. Sample quality was
assessed by examination of the 3 to 5 intensity ratios of certain genes.
RESULTS
R activates FAS expression. To examine the effect of R on
cellular gene expression, we performed microarray analyses
using an Affymetrix chip containing 5,000 cellular genes, with
RNA isolated from telomerase-immortalized human primary
keratinocytes (TIK) which were mock infected, infected with
an adenovirus vector expressing LacZ (AdLacZ) or infected
with an adenovirus vector expressing R (AdR). The microarray
analysis results indicated that cells infected with AdR ex-
pressed the cellular FAS gene at a level seven times higher
than that of the mock-infected cells or AdLacZ-infected cells
(data not shown).
To confirm that R activates FAS expression, we performed
Northern blot analysis of the RNA obtained from TIK and
HeLa cells which were mock infected or infected with the
AdLacZ or AdR vector. Compared to the mock-infected and
AdLacZ-infected cells, both TIK and HeLa cells infected with
the AdR vector had significantly increased levels of FAS
mRNA (Fig. 1A). In addition, HeLa cells transfected with an
R expression vector produced considerably more FAS than
cells transfected with a control plasmid (Fig. 1B). These results
indicate that R activates FAS gene expression in both HeLa
and TIK cells and that this effect is not dependent upon the
adenovirus vector. To confirm that R expression also induces
increased FAS protein, immunofluorescence analysis of Ad-
LacZ- or AdR-infected TIK cells was performed (Fig. 1C).
AdR infection, as expected, significantly increased the level of
FAS protein in TIK cells.
FAS is overexpressed in epithelial tongue cells derived from
OHL. To determine whether FAS expression is increased by
lytic EBV infection, we examined FAS expression in epithelial
cells in the lateral tongue using biopsy specimens obtained
from healthy individuals versus tongue biopsy specimens from
patients with OHL. OHL is a lesion induced by lytic EBV
infection of the tongue in immunosuppressed patients (21, 68).
As expected, Z expression was observed in the condensed
nuclei of koilocyte cells in the mid to upper strata in biopsy
specimens of OHL lesions (data not shown), confirming that
these cells contained the lytic form of EBV infection. Cyto-
plasmic FAS expression was observed in OHL tissue in the mid
to upper strata within the stratum spinosum and stratum
granulosum layer, but not in the control tongue tissue (Fig. 2).
These results indicate that FAS protein expression is induced
by lytic EBV infection in tongue epithelial cells.
R activation of FAS requires p38 stress MAP kinase. FAS
expression is primarily induced in normal cells in response to
low sterol levels. This effect is mediated by the activated,
cleaved form of the sterol regulatory element binding proteins
(SREBPs), which are transported into the nucleus and bind
directly to the FAS promoter (35, 50). However, overexpres-
sion of FAS in cancer cell lines has recently been attributed to
PI3 kinase or MAP kinase activation (57, 67). To determine
whether R activates FAS expression through a PI3 kinase or
p38 stress MAP kinase-dependent mechanism, we infected
TIK cells with the control adenovirus vector (AdLacZ) or the
R adenovirus vector in the presence or absence of the PI3
kinase inhibitor, LY294002, or the p38 kinase inhibitor
(SB202190). In addition, the effect of a FAS inhibitor, cerule-
nin, was also examined. Total RNA was isolated 24 h postin-
fection, and Northern blot analysis was performed to detect
FAS mRNA expression. Interestingly, the p38 kinase inhibitor
completely prevented AdR-induced FAS activation in TIK
cells, while the PI3 kinase inhibitor had less effect (Fig. 3, top
panel). The FAS inhibitor did not affect R activation of the
FAS gene. The levels of R protein were similar in all condi-
tions (Fig. 3, bottom panel). These results suggest that p38
kinase activity is required for R-induced FAS activation.
FAS inhibitors prevent R-mediated lytic viral gene induc-
tion. The previous results indicate that R activates FAS ex-
pression in host cells during lytic EBV infection. To determine
whether cellular FAS activity is important for some aspect of
lytic EBV infection, we examined the effects of two different
specific FAS inhibitors, cerulenin and C75. Cerulenin is a nat-
ural product produced by certain fungi that specifically inhibits
FAS activity by covalently binding to the beta keto acyl syn-
thase moiety, one of the seven functional domains of FAS (12,
37, 40). C75 is a synthetic compound that also specifically
inhibits FAS activity (30).
To determine whether the ability of R to activate lytic EBV
gene expression requires FAS activity, Jijoye cells were elec-
troporated with the SG5 control vector or SG5 vectors that
express R (SG5-R) or Z (SG5-Z). After electroporation, cells
were treated with a FAS inhibitor (cerulenin or C75) or vehicle
(DMSO) and then harvested for immunoblot analysis of R, Z,
and BMRF1 expression 48 h posttransfection. The ability of
transfected R to induce Z or BMRF1 expression in Jijoye cells
was almost completely eliminated by both the cerulenin and
C75 FAS inhibitors (Fig. 4), although these inhibitors did not
reduce R expression derived from the SG5-R vector. Thus,
cellular FAS activity unexpectedly appears to be critical for the
ability of R to activate Z expression from the latent EBV
genome. Since both Z and R are required for efficient expres-
sion of the BMRF1 early gene from the intact viral genome (1,
18), the failure of R to activate BMRF1 expression in the
presence of the FAS inhibitors may reflect its inability to ac-
tivate Z.
Assuming that FAS activity is primarily important for R
activation of Z transcription, then a vector which expresses the
Z gene product under the control of a constitutively active
heterologous promoter should be able to induce lytic EBV
gene expression even in the presence of the FAS inhibitors. As
shown in Fig. 4, this did indeed prove to be the case. Neither
cerulenin nor C75 significantly inhibited the ability of the
SG5-Z expression vector (in which Z is driven by the simian
virus 40 early promoter) to induce R or BMRF1 expression
from the endogenous viral genome in Jijoye cells. These results
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FIG. 1. R induces FAS expression. (A) Telomerase-immortalized primary keratinocytes (TIK) and HeLa cells were either mock infected or
infected with adenovirus vectors encoding -galactosidase (AdLacZ) or R (AdR) at an MOI of 20. Twenty-four hours postinfection, total RNA
was isolated, and Northern blot analysis was performed to detect FAS expression. (B) HeLa cells were transfected with the control vector, SG5,
or an SG5 vector expressing R (SG5-R). Total RNA was isolated 24 h after transfection, and Northern blot analysis was performed. In panels A
and B, the positions of FAS and glyceraldehyde phosphate dehydrogenase (GAPDH) are indicated by the arrows. (C) TIK cells were infected with
adenovirus vectors encoding -galactosidase (AdLacZ) or R (AdR) at an MOI of 20. Cells were analyzed by immunofluorescence microscopy 24 h
later using FAS antibody (Ab) or a control antibody (left panels) or stained with DAPI (right panels).
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suggest that FAS activity plays an important role in R-medi-
ated lytic viral induction and more specifically that FAS activity
is required for R activation of Z transcription in the context of
the intact latent viral genome.
FAS inhibitors prevent lytic EBV induction after cross-link-
ing of the B-cell receptor. We have previously shown that
certain cellular kinases which are required for R activation of
Z transcription, including PI3 kinase and the stress MAP ki-
nase p38, are likewise required for the induction of Z tran-
scription after B-cell receptor stimulation in Akata cells (3, 13).
Therefore, we examined whether cellular FAS activity is also
required for activation of lytic EBV gene transcription induced
by cross-linking of the B-cell receptor, since this method may
be the most physiological model of activating lytic EBV infec-
tion in B cells in vitro (55). Akata cells were treated with
cerulenin, C75, or DMSO for 1 h, followed by the addition of
anti-human IgG to the medium for 24 h. Cell extracts were
then prepared for immunoblot analysis of R, Z, and BMRF1
expression. As shown in Fig. 5, cross-linking of the B-cell
receptor, as expected, efficiently induced R, Z, and BMRF1
expression in the absence of the FAS inhibitors. However, both
cerulenin and C75 dramatically decreased the ability of B-cell
receptor engagement to induce R, Z, and BMRF1 expression
in Akata cells (Fig. 5). Akata cell viability in the presence of
the FAS inhibitors was greater than 90% (data not shown).
These results suggest that FAS activity is also required for the
lytic viral gene expression that normally follows B-cell receptor
stimulation.
FAS inhibitors prevent constitutively lytic EBV gene expres-
sion in AGS cells. We have previously shown that AGS (gastric
carcinoma) cells stably infected with EBV have a relatively
high proportion of cells (3 to 5%) which spontaneously convert
FIG. 2. FAS is overexpressed in OHL. Tongue biopsy specimens from a patient with OHL or a healthy individual were stained with either an
anti-FAS antibody (Ab) or a control primary antibody, followed by a FITC-conjugated second antibody (left panels). DAPI staining was also
performed (right panels). FAS protein expression was then examined using confocal fluorescence microscopy.
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to the lytic form of EBV infection in the absence of any par-
ticular inducing stimuli (36). Although the cellular factors that
induce lytic EBV infection in AGS cells are not well under-
stood, this model system is potentially more relevant for ex-
amining the constitutively lytic EBV infection which occurs in
epithelial cells (such as OHL lesions) than are studies per-
formed in Jijoye and Akata cells. To determine the importance
of FAS activity for spontaneously lytic EBV infection in AGS
cells, confluent EBV-positive AGS cells were treated with
DMSO, cerulenin (5 g/ml,) or C75 (5 g/ml), and cells were
harvested 48 h later for immunoblot analysis of R, Z, and
BMRF1 expression. The R, Z, and BMRF1 proteins were all
expressed in EBV-positive AGS cells in the absence of FAS
inhibitors, but both cerulenin and C75 reduced expression of
all three lytic viral proteins (Fig. 6). Cell viability of confluent
EBV-positive AGS cells in the presence of the FAS inhibitors
was greater than 90% (data not shown). These results suggest
that cellular FAS activity is also required for the spontaneous
lytic EBV infection that normally occurs in AGS cells.
FAS inhibitors do not prevent R activation of Zp in a naked
DNA reporter gene assay. The previous results clearly indicate
that FAS activity is required for the ability of R to activate Z
transcription from the intact latent viral genome. To determine
whether the FAS effect could be further dissected using re-
porter gene assays, Jijoye cells were transfected with a reporter
gene construct containing the CAT gene driven by the Z pro-
moter (Zp-CAT) in the presence or absence of the R expres-
sion vector, and the ability of the FAS inhibitors (C75 and
cerulenin) to prevent R-induced activation of the Zp-CAT
FIG. 3. R activation of FAS requires p38 kinase. TIK cells were
treated with a p38 kinase inhibitor (SB202190 [20 M]), a PI3 kinase
inhibitor (LY294002 [15 M)], or a FAS inhibitor (cerulenin [5 g/
ml]) for 1 h and then infected with AdLacZ or AdR at an MOI of 50.
Total RNA was isolated 24 h postinfection, and Northern blot analysis
was performed to detect FAS and glyceraldehyde phosphate dehydro-
genase (GAPDH) expression. Immunoblot analysis was performed in
the same experiment to detect BRLF1 protein expression.
FIG. 4. FAS inhibitors (cerulenin and C75) prevent R-mediated, but not Z-mediated, lytic EBV induction. Jijoye cells were electroporated with
10 g of a control vector (SG5), an R expression vector (SG5-R), or a Z expression vector (SG5-Z), in the presence () or absence () of two
different FAS inhibitors, cerulenin (10 g/ml) or C75 (10 g/ml). Cell extracts were prepared 48 h posttransfection, and immunoblot analysis was
performed to detect IE (R and Z) and early (BMRF1) lytic EBV protein expression.
FIG. 5. FAS activity is required for lytic EBV induction after B-cell
receptor engagement in Akata cells. EBV-positive Akata cells (a Bur-
kitt’s lymphoma line) were treated with anti-IgG () to induce lytic
EBV expression in the presence () or absence () of FAS inhibitor
cerulenin (5 g/ml) or C75 (5 g/ml). Cell extracts were prepared 24 h
after treatment, and immunoblot analysis was performed to detect R,
Z, and BMRF1 protein expression.
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vector was examined. As shown in Fig. 7, the C75 inhibitor did
not significantly affect the ability of R to activate the Zp-CAT
construct, even though an immunoblot analysis of the same
extracts used in the CAT assay indicated that C75 inhibited the
ability of R to activate Z transcription from the endogenous
viral genome (data not shown). Likewise, cerulenin did not
significantly inhibit the ability of R to activate the Zp-CAT
construct (data not shown). These results indicate that FAS
activity may help to induce Z transcription in the context of the
intact virus by reversing an epigenetic modification (such as an
inhibitory chromatin structure or viral genome methylation)
that cannot be modeled using naked Zp DNA. Alternatively, it
is possible that a FAS-responsive region of the Zp lies outside
the sequences present in our Zp-CAT construct (positions
221 to 12).
B-cell receptor engagement activates FAS expression. Cur-
rently, little is known regarding the regulation of FAS expres-
sion in B cells. Since activation of the B-cell receptor induces
lytic EBV gene expression and we previously found that R
induces many of the same signal transduction pathways that
are activated by B-cell receptor engagement (3, 13), we wished
to determine whether B-cell receptor engagement, like R, also
results in enhanced FAS expression. The level of FAS RNA in
Akata cells (both EBV positive and EBV negative) was quan-
titated by RT-PCR analysis with or without anti-IgG treat-
ment. As shown in Fig. 8, B-cell receptor stimulation resulted
in an increased level of FAS RNA expression in both EBV-
negative and EBV-positive Akata cells. Thus, enhanced FAS
expression may be a downstream component of the B-cell
receptor signaling pathway which is required for induction of
lytic EBV gene expression.
DISCUSSION
Expression of the EBV IE protein R is sufficient to initiate
the switch from the latent to lytic form of viral infection in
many EBV-positive cell lines. In this report, we demonstrate
that R activates the expression of the cellular FAS gene in
HeLa and TIK cells. In addition, we show that FAS expression
FIG. 6. FAS activity is required for constitutive lytic viral gene
expression in EBV-positive AGS (gastric carcinoma) cells. EBV-pos-
itive AGS cells were treated with () or without () cerulenin (5
g/ml) or C75 (5 g/ml) for 48 h, and cells were harvested for immu-
noblot analysis. Extracts from EBV-negative () AGS cells (leftmost
lane) were used as a negative control.
FIG. 7. FAS activity is not required for R activation of Zp in a reporter gene assay. Jijoye cells were transfected with the Zp-CAT construct
(in which the CAT gene is linked to the Z promoter) in combination with either the SG5 control vector or the SG5-R expression vector in the
presence () or absence () of cerulenin. Cells were harvested for CAT activity assay 72 h posttransfection.
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is elevated within lytically infected epithelial cells of OHL
lesions in patients. Most importantly, we show that FAS activ-
ity is essential for efficient induction of lytic EBV gene tran-
scription by a variety of different stimuli. The ability of R to
induce FAS expression in cells which would normally express
minimal FAS (such as primary epithelial cells and B cells) may
therefore be important for efficient lytic EBV infection. Our
finding that B-cell receptor stimulation in both EBV-positive
and EBV-negative Akata cells also results in enhanced FAS
expression suggests that increased FAS activity may likewise
play a role in anti-IgG mediated lytic EBV induction.
Although many transformed cell lines constitutively express
high levels of FAS in vitro, high-level expression of FAS in vivo
is restricted to liver, lung, brain, and adipose tissue (50). FAS
expression is tightly regulated at the transcriptional level and is
induced in normal cells primarily in response to low sterol
levels. Sterol-responsive FAS transcription is mediated by
SREBPs. SREBPs exist in an inactive form bound to the en-
doplasmic reticulum (26, 50). Intracellular lipid depletion trig-
gers proteolytic cleavage of SREBPs, allowing the amino ter-
minus to enter the nucleus and activate the expression of genes
encoding enzymes involved in de novo fatty acid synthesis (26,
50). In contrast, FAS overexpression in cancer cell lines is
mediated primarily through activation of the PI3 kinase and
MAP kinase signal transduction pathways (57, 67). Our results
here suggest that R activation of FAS requires the p38 stress
MAP kinase pathway.
FAS activity is required for de novo synthesis of palmitate, a
fatty acid. At present, it is not clear how cellular FAS activity
contributes to lytic EBV gene induction. However, our results
here suggest that this requirement for FAS activity occurs at
the most proximal step in the activation of the lytic EBV gene
transcription cascade, the induction of IE gene transcription.
In addition, it appears that cellular FAS activity is required for
the effectiveness of a variety of different lytic inducing stimuli
and in a variety of different cell types. FAS inhibitors not only
prevented the ability of R to induce lytic EBV gene expression
in Jijoye cells but also prevented lytic EBV gene expression
after ligation of the B-cell receptor in Akata cells, as well as the
spontaneous lytic viral gene expression that normally occurs in
EBV-infected gastric carcinoma cells.
Whatever the mechanism, our results suggest that FAS ac-
tivity may be primarily required for activation of Z transcrip-
tion, rather than R transcription, from the intact viral genome.
A Z expression vector in which the Z gene product is driven by
a strong heterologous promoter can activate R transcription
(as well as early gene transcription) from the endogenous viral
genome even in the presence of FAS inhibitors. In contrast, an
expression vector containing the R gene product driven by the
same heterologous promoter cannot activate Z transcription
(or downstream early genes).
Nevertheless, we found that FAS inhibitors reduce expres-
sion of both IE proteins (Z and R) in spontaneously lytic AGS
cells and after ligation of the B-cell receptor in Akata cells.
The ability of FAS inhibitors to reduce R, as well as Z, expres-
sion under these conditions could be due to either of the
following explanations. If we assume that induction of lytic
EBV transcription is initially mediated through cellular acti-
vation of Zp, then the ability of cellular transcription factors to
induce Z expression from the latent viral genome (in the ab-
sence of any R expression) may also require FAS activity. In
this model, the loss of Z expression induced by FAS inhibitors
then results in the loss of R expression, since the Z gene
product is not available to activate R transcription. If lytic
induction is primarily initiated through cellular activation of
the R promoter and the R gene product then activates Z
expression, we can still explain the loss of both R and Z
expression in the presence of the FAS inhibitors, since an
essential aspect of lytic EBV gene induction is the positive
autoregulatory cascade resulting from the ability of Z to acti-
vate R transcription and vice versa. By preventing even one
part of this autoregulatory cascade (the ability of R to induce
Z transcription), lytic EBV induction by a variety of different
stimuli may be effectively attenuated.
Although we do not currently understand why FAS activity
is required for activation of Z transcription, there are a variety
of potential possibilities. One possibility is that the level of
palmitate in the cell is limiting in the absence of de novo fatty
acid synthesis. A variety of proteins are known to be posttrans-
lationally modified by palmitoylation over cysteine residues,
and in some cases this modification is important for the local-
ization of proteins into lipid rafts. Palmitoylation has been
FIG. 8. FAS is activated by B-cell receptor engagement in EBV-negative and EBV-positive Akata cells. EBV-negative and EBV-positive Akata
cells were treated with anti-human IgG (0.1 mg/ml) for 24 h () or not treated with anti-IgG (), and cells were then harvested for RNA isolation.
RT-PCR was performed to detect FAS or 2-microglobulin RNA expression. Control experiments without reverse transcriptase (RT) were also
performed.
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shown to be required for the correct cellular localization
and/or function of a variety of proteins, including p21 Ras (6,
14), and we have previously shown that Ras is required for
efficient lytic EBV infection (13). Fyn and Lck (the Src family
kinases), which are important for the signal transduction path-
ways resulting from activation of the B-cell and T-cell recep-
tors, are also palmitoylated (58, 59, 66). In addition, enhanced
FAS activity could potentially lead to activation of signal trans-
duction pathways dependent upon fatty acid precursors. For
example, de novo synthesis of the lipid mediator ceramide
requires palmitate, and exogenous palmitate treatment of cells
has been shown to induce de novo ceramide synthesis in some
cells (5, 41, 49). Ceramide-induced signal transduction path-
ways include some of the same pathways (PI3 kinase, JNK, and
p38 stress MAP kinase) (5, 45, 65) activated by R (3, 13).
However, we have not found that an inhibitor of de novo
ceramide synthesis, fumonisin, inhibits the ability of R to in-
duce lytic infection (unpublished data).
Perhaps most importantly, our results here suggest a com-
pletely novel approach for inhibiting the lytic form of EBV
replication. FAS inhibitors, such as C75 and cerulenin, inhibit
EBV replication at a much earlier step (prevention of IE gene
transcription) than the currently used antiviral drugs, such as
acyclovir, which block viral DNA replication but do not pre-
vent IE and early gene transcription. Furthermore, C75 is
apparently nontoxic in mice (other than causing obese mice to
lose weight) and is being investigated as an agent to treat
obesity (31, 34). Interestingly, the active agent in green tea
(epigallocatechin gallate) was recently shown to inhibit expres-
sion of lytic EBV genes in response to 12-O-tetradecanoyl-
phorbol-13-acetate induction (7) and was also found to directly
bind to FAS and inhibit its activity (61). Thus, inhibition of
FAS activity may prove to be an effective and potentially non-
toxic method for inhibiting lytic EBV replication in patients.
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